Core Points - The announcement from Huaxia Eye Hospital indicates the lifting of restrictions on shares issued prior to its initial public offering (IPO) [1] - A total of 511,170,000 shares will be released, representing 60.8536% of the company's total share capital [1] - The lifting of restrictions will take effect on November 7, 2025, after a 36-month lock-up period following the IPO [1]

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 首次公开发行前已发行股份解除限售 并上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所 创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 以及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 相关法律、法规和规范性文件的规定，对华厦眼科首次公开发行前已发行股份解除限售 并上市流通的事项进行了审慎核查，具体情况如下： 一、首次公开发行股票和股本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕2085 号）同意，华厦眼科医院集团股份有限公 司首次公开发行人民币普通股（A 股）股票 6,000.00 万股，并于 2022 年 11 月 7 日在深 圳证券交易所创业板上市交易。 首次公开发行股票完成后公司总股本为 56,00 ...

华厦眼科医院集团股份有限公司 关于首次公开发行前已发行股份解除限售 并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为华厦眼科医院集团股份有限公司（以下简称"公 司"）首次公开发行前已发行的股份。 2、本次解除限售的股东户数为 2 户，解除限售股份数量共计 511,170,000 股， 占公司总股本的比例为 60.8536%，限售期为自公司首次公开发行股票上市之日 起 36 个月。 3、本次解除限售股份的上市流通日为 2025 年 11 月 7 日（星期五）。 一、首次公开发行股票和股本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕2085 号）同意，华厦眼科医院 集团股份有限公司首次公开发行人民币普通股（A 股）股票 6,000.00 万股，并于 2022 年 11 月 7 日在深圳证券交易所创业板上市交易。 证券代码：301267 证券简称：华厦眼科 公告编号：2025-034 首次公开发行股票完成后公司总股本为 56,000 ...

Core Points - In November 2025, a total of 124 companies in the A-share market will have their restricted shares unlocked, amounting to approximately 8.952 billion shares with a total market value of 160.677 billion yuan, representing a month-on-month decrease of about 26.45% and a year-on-year decrease of about 44.64% [1][8] Company Summaries - Ruijie Networks has the largest unlock scale, with 700 million shares set to be released on November 20, valued at approximately 52.78 billion yuan, accounting for 88% of its total share capital [3][4] - Innovation New Materials will have 2.287 billion restricted shares unlocked on November 17, with a market value of about 10.222 billion yuan, involving shareholders such as Shandong Innovation Group and Beijing Hualian Group [6][8] - Huaxia Eye Hospital ranks third in unlock scale, with 511.7 million shares, representing 60.85% of its total share capital, valued at approximately 9.814 billion yuan [6][8] Industry Insights - The telecommunications, pharmaceutical, and electronics industries have the highest unlock market values, with Ruijie Networks leading in telecommunications, while Huaxia Eye Hospital and New Nobel are notable in the pharmaceutical sector [8][10] - In total, seven companies will celebrate their listing anniversary in November, with a combined unlock volume of approximately 390 million shares and a market value of about 12.262 billion yuan [10]

Core Viewpoint - In November 2025, a total of 124 companies in the A-share market will face the unlocking of restricted shares, amounting to approximately 8.952 billion shares with a total market value of 160.677 billion yuan, reflecting a month-on-month decrease of about 26.45% and a year-on-year decrease of about 44.64% [1][2]. Group 1: Unlocking Scale and Key Companies - The largest unlocking scale is attributed to Ruijie Networks, with a market value exceeding 50 billion yuan [1][3]. - The top three companies by unlocking scale are Ruijie Networks, Innovation New Materials, and Huaxia Eye Hospital [3][10]. - Ruijie Networks will have 700 million shares unlocked on November 20, with a market value of approximately 52.78 billion yuan, accounting for 88% of its total share capital [3][4]. Group 2: Industry Distribution - The industries with the highest unlocking market values are telecommunications, biomedicine, and electronics [10]. - In the telecommunications sector, Ruijie Networks significantly contributes to the unlocking scale, while in biomedicine, Huaxia Eye Hospital, New Nobel, and New World lead in unlocking market value [10]. Group 3: Anniversary Unlocking - Seven companies will have 39 million restricted shares unlocked in November, with a total market value of 12.262 billion yuan, including companies like Juxing Technology and Jintian Titanium Industry [1][9]. - Juxing Technology has the largest anniversary unlocking scale at approximately 3.307 billion yuan, followed by Jintian Titanium Industry and Wanyuantong with 3.195 billion yuan and 3.011 billion yuan, respectively [14].

Group 1 - The core issue is that Qingyue Technology (688496) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false financial reporting, which could lead to a forced delisting if found guilty [1][2] - The company reported a total revenue of 476 million yuan for the third quarter of 2025, a year-on-year decrease of 13.64%, and a net profit attributable to shareholders of -43.35 million yuan, an increase of 11.3% year-on-year [1] - The stock closed at 8.94 yuan per share, with a market capitalization of 4.023 billion yuan [1] Group 2 - Next week, 30 stocks will face a total unlock market value of 20.322 billion yuan, with Huaxia Eye Hospital having the largest unlock value of 9.993 billion yuan [4][5] - The highest unlock ratio is for Huaxia Eye Hospital at 60.85%, followed by several other companies with significant unlock ratios [6] - The average stock price of the 30 stocks facing unlock has decreased by 1.89% since October, with some stocks like Transsion Holdings experiencing a significant drop of 19% [9]

Core Viewpoint - Next week, 30 stocks will have their restrictions lifted, with a total market value of 20.322 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - Huaxia Eye Hospital will have 511 million shares available for trading, primarily consisting of original shareholders' restricted shares, with a market value of 9.993 billion yuan, the highest among the stocks [1] - Yunding Technology follows with 153 million shares to be unlocked, mainly from the placement of shares to targeted investors, with a market value of 1.74 billion yuan [1] Group 2: Unlocking Ratios - Huaxia Eye Hospital has the highest unlocking ratio at 60.85% [1] - Other companies with significant unlocking ratios include Hongbo Pharmaceutical, Naike Equipment, Yunding Technology, Ruina Intelligent, and Gangdi Technology [1]

Investment Rating - The report maintains an "Outperform" rating for Huaxia Eye Hospital Group, with a target price set at 21.08 RMB based on a 40x PE valuation of the 2025 net profit [8][9]. Core Insights - The report forecasts revenue for 2025-2027 at 4.21 billion, 4.63 billion, and 5.15 billion RMB, with growth rates of 4.6%, 9.8%, and 11.3% respectively. Net profit attributable to shareholders is projected at 443 million, 503 million, and 586 million RMB, growing by 3.3%, 13.6%, and 16.6% [8][9]. - The company is focusing on "organic growth + external M&A" strategy, having successfully acquired Chengdu Aidi Eye Hospital in 2024, enhancing its position as a large medical chain with two top-tier eye hospitals [9][10]. - Huaxia Eye Hospital is actively introducing cutting-edge technology and procedures, maintaining a leading position in ophthalmic innovation, particularly in refractive and cataract surgeries [10][11]. - The company is enhancing its medical quality management and research innovation, aiming to create a high-quality service system driven by innovation in eye disease treatment [11]. Financial Summary - The financial summary indicates total revenue for 2023 at 4,013 million RMB, with a projected increase to 4,212 million RMB in 2025, reflecting a growth of 4.6%. Net profit for 2023 is 666 million RMB, expected to decrease to 443 million RMB in 2024 before recovering to 586 million RMB by 2027 [3][5]. - The report highlights a decline in net profit margin from 16.9% in 2023 to 10.5% in 2025, with a gradual recovery to 11.4% by 2027 [5].

Core Insights - Huaxia Eye Hospital (301267.SZ) released its Q3 2025 report, indicating that as of October 28, 2025, 11 institutional investors held a total of 442 million shares, representing 52.60% of the total share capital [1] - The top ten institutional investors collectively held 52.06% of the shares, with a slight decrease of 0.14 percentage points compared to the previous quarter [1] Institutional Holdings - The top ten institutional investors include Huaxia Medical Investment (Xiamen) Co., Ltd., Xiamen Hanwei Equity Investment Partnership (Limited Partnership), and several other Xiamen-based investment firms [1] - One public fund, Huabao Zhongzheng Medical ETF, reported a decrease in holdings by 0.14% compared to the previous quarter [1] - A total of 180 public funds did not disclose their holdings this quarter, including notable funds such as E Fund ChiNext ETF and Southern CSI 500 ETF [1]

Core Viewpoint - Huaxia Eye Hospital (301267.SZ) reported a revenue of 3.272 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.83% [1] - The net profit attributable to shareholders reached 434 million yuan, marking a year-on-year increase of 3.04% [1] - The net profit excluding non-recurring gains and losses was 423 million yuan, with a year-on-year increase of 1.65% [1] - Basic earnings per share stood at 0.52 yuan [1] Financial Performance - Revenue for the first three quarters: 3.272 billion yuan, up 2.83% year-on-year [1] - Net profit attributable to shareholders: 434 million yuan, up 3.04% year-on-year [1] - Net profit excluding non-recurring items: 423 million yuan, up 1.65% year-on-year [1] - Basic earnings per share: 0.52 yuan [1]